• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

    12/11/23 9:00:00 AM ET
    $HNST
    $LUNG
    Catalog/Specialty Distribution
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $HNST alert in real time by email

    LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023.

    "We are pleased to welcome Michael, Alissa and Andrea to our board of directors. All three leaders are proven experts in the consumer goods space. Their retail and digital expertise will strengthen our board by adding significant capabilities that support the company's growth plans." said Carla Vernón, CEO of The Honest Company. "I look forward to partnering with our entire board as we continue to advance our Transformation Initiative and long-term strategy in 2024."

    Barkley, a seasoned consumer products executive, most recently served as the CEO of KIND LLC. At KIND, Barkley led the business through a new era of growth and expansion. He also spearheaded transformational change and performance acceleration at Pinnacle Foods and Johnson & Johnson. Barkley is a visionary leader who builds organizational capabilities to enable high-performing teams and deliver enduring value creation.

    Lynch is an experienced industry leader across consumer products, healthcare, and technology. At Google, she worked with Fortune 500 companies to drive digital transformation in healthcare using data, analytics, and AI. Previously, she was Vice President at Johnson & Johnson, where she held P&L and strategy roles leading billion-dollar global businesses in the MedTech and Consumer Health sectors, including Baby and Skin Care. She currently serves on the Board of Directors of Pulmonx (NASDAQ:LUNG).

    Turner, a global leader in supply chain and logistics management has a successful background which includes transformational impact at Fortune 500 companies across consumer goods, biotech and pharmaceuticals. As Senior Vice President, Global Customer Service and Logistics at Mondelēz, she strategized and led logistics during the COVID-19 pandemic for the $25 billion supply chain across 80 countries. Turner was also responsible for driving teams to solve complex supply chain problems at General Mills and Merck, delivering improved productivity and accelerating growth.

    "Honest continues to drive strong performance and demonstrate the power of our brand. As we continue on this journey to drive stakeholder value, we welcome Michael, Alissa and Andrea's expertise. They join Honest during an exciting and pivotal time for the brand and I am confident these additions further transform the board as the company evolves our growth strategy," said James D. White, Chair of the Board of The Honest Company. "Their diverse backgrounds and areas of expertise will help elevate us to new heights for consumers and push our thinking even further."

    Forward-Looking Statements

    All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the Company's performance and brand and the Company's ability to deliver on its Transformation Initiative and drive stakeholder value. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this press release primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled "Risk Factors" in the Annual Report, on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 16, 2023, and Quarterly Report on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, respectively, filed with the Securities and Exchange Commission on May 9, 2023, August 8, 2023 and November 8, 2023, respectively, and subsequent filings with the Securities and Exchange Commission. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or the earnings call referencing this press release. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

    About The Honest Company

    The Honest Company (NASDAQ:HNST) is a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care. Honest products are available via Honest.com, third-party ecommerce customers and approximately 51,000 retail locations across the United States, Canada and Europe. Based in Los Angeles, CA, the Company's mission, to inspire everyone to love living consciously, is driven by its values of transparency, trust, sustainability and a deep sense of purpose around what matters most to its consumers: their health, their families and their homes. For more information about the Honest Standard and the Company, please visit www.honest.com.

    Investor Contact:

    Elizabeth Bouquard

    [email protected] 

    Media Contact:

    Jennifer Kroog Rosenberg

    [email protected] 



    Primary Logo

    Get the next $HNST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HNST
    $LUNG

    CompanyDatePrice TargetRatingAnalyst
    The Honest Company Inc.
    $HNST
    8/7/2025$7.00 → $6.00Market Perform
    Telsey Advisory Group
    Pulmonx Corporation
    $LUNG
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    Pulmonx Corporation
    $LUNG
    3/10/2025$17.00Buy
    D. Boral Capital
    The Honest Company Inc.
    $HNST
    1/10/2025$6.00 → $7.00Market Perform
    Telsey Advisory Group
    The Honest Company Inc.
    $HNST
    12/17/2024$7.00Buy → Hold
    Loop Capital
    Pulmonx Corporation
    $LUNG
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    The Honest Company Inc.
    $HNST
    11/13/2024$4.00 → $6.00Market Perform
    Telsey Advisory Group
    The Honest Company Inc.
    $HNST
    11/13/2024$5.75 → $8.00Buy
    Alliance Global Partners
    More analyst ratings

    $HNST
    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Honest Company with a new price target

    Telsey Advisory Group reiterated coverage of Honest Company with a rating of Market Perform and set a new price target of $6.00 from $7.00 previously

    8/7/25 6:46:22 AM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    Pulmonx downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Pulmonx from Overweight to Neutral and set a new price target of $2.50

    7/31/25 7:16:23 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on Pulmonx with a new price target

    D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

    3/10/25 8:07:21 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HNST
    $LUNG
    SEC Filings

    View All

    SEC Form 144 filed by The Honest Company Inc.

    144 - Honest Company, Inc. (0001530979) (Subject)

    8/21/25 6:36:17 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-Q filed by The Honest Company Inc.

    10-Q - Honest Company, Inc. (0001530979) (Filer)

    8/6/25 4:18:29 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    The Honest Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Honest Company, Inc. (0001530979) (Filer)

    8/6/25 4:16:51 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    $HNST
    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Honest Company Reports Second Quarter 2025 Results

    Transformation Pillars Continue to Drive Profitability Improvement, Gross Margin Expansion and Revenue GrowthDelivers Net Income of $4 Million and Gross Margin of 40.4%, Expansion of 210 Basis PointsReaffirms Full Year 2025 Financial Outlook LOS ANGELES, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today reported financial results for the three and six months ended June 30, 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period: Revenue of $93 million increased 0.4%Gross margin of 40.4% expanded 210 basis pointsNet income of $4 million, increas

    8/6/25 4:05:00 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    Pulmonx Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15% increase over the same period last year and an increase of 13% on a constant currency basisDelivered $9.1 million in international revenue in the second quarter of 2025, representing 32% year-over-year growth and an increase of 27% on a constant currency basisDelivered $14.7 million in U.S. revenue in the second qu

    7/30/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference

    REDWOOD CITY, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Canaccord Genuity 45th Annual Growth Conference in Boston on Tuesday, August 12, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® E

    7/29/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HNST
    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HNST
    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Ball Dorria L. sold $17,724 worth of shares (4,856 units at $3.65), decreasing direct ownership by 2% to 267,391 units (SEC Form 4)

    4 - Honest Company, Inc. (0001530979) (Issuer)

    8/21/25 9:55:10 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    SVP, Customer Sales Mayle Jonathan sold $17,542 worth of shares (4,806 units at $3.65), decreasing direct ownership by 2% to 298,146 units (SEC Form 4)

    4 - Honest Company, Inc. (0001530979) (Issuer)

    8/21/25 9:50:50 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    Chief Executive Officer Vernon Carla sold $362,547 worth of shares (99,328 units at $3.65), decreasing direct ownership by 3% to 2,998,993 units (SEC Form 4)

    4 - Honest Company, Inc. (0001530979) (Issuer)

    8/21/25 9:46:30 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    $HNST
    $LUNG
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Second Quarter 2025 Financial Results

    REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2025 ended June 30, 2025. Recent Highlights Achieved worldwide revenue of $23.9 million in the second quarter of 2025, a 15% increase over the same period last year and an increase of 13% on a constant currency basisDelivered $9.1 million in international revenue in the second quarter of 2025, representing 32% year-over-year growth and an increase of 27% on a constant currency basisDelivered $14.7 million in U.S. revenue in the second qu

    7/30/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    The Honest Company to Report Second Quarter Financial Results on August 6, 2025

    LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today announced that it will report second quarter 2025 financial results after the market closes on Wednesday, August 6, 2025. The Company will host an investor conference call and webcast to review second quarter 2025 financial results at 1:45pm PT/4:45pm ET on the same day. The live webcast can be accessed at https://investors.honest.com. For those interested in participating in the conference call by phone, please go to this link: https://register-conf.media-server.com/register/BIb4de1d68621a49d3a9db6b0d71e

    7/23/25 4:05:00 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025

    REDWOOD CITY, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2025 after the close of trading on Wednesday, July 30, 2025. Thereafter, company management will host a conference call to discuss the results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive

    7/16/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $HNST
    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    2/21/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    The Honest Company Announces Appointment of Dorria L. Ball as Chief People Officer

    LOS ANGELES, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The Honest Company, a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced Dorria L. Ball as the Company's new Chief People Officer (CPO), effective immediately. Ball has served in this role on an interim basis since August of 2023. Reporting directly to Carla Vernón, CEO of The Honest Company, Ball will continue working alongside Honest's executive leadership team and Board of Directors as the leader of the People & Workplace function. "At Honest, we believe that values, business performance, DEI, and

    1/5/24 4:00:00 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    $HNST
    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by The Honest Company Inc.

    SC 13G/A - Honest Company, Inc. (0001530979) (Subject)

    11/14/24 6:19:57 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by The Honest Company Inc.

    SC 13G/A - Honest Company, Inc. (0001530979) (Subject)

    11/14/24 5:53:21 PM ET
    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary